Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma
2018-000050-22Phase 2Active
- Sponsor
- Skåne University Hospital
- Start
- Mar 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, oxaliplatin, fluorouracil and folinic acid in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Skåne University Hospital. Primary endpoint: Histopathological response rate. Started Mar 2018; status: active.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2018-000050-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000050-22.